Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ubrogepant vs Sumatriptan Dermal Blood Flow
NCT05654298Phase 1Completed
- Sponsor
- UZ Leuven
- Start
- Mar 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of ubrogepant in migraine (2 arms), sponsored by UZ Leuven. Primary endpoints: Change in Dermal Blood Flow induced by topical application of cinnamaldehyde, Change in Dermal Blood Flow induced by topical application of capsaicin and 1 more. Started Mar 2022; status: completed.
02
Drugs
ubrogepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05654298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05654298.